Neil J. Gallagher

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil et al. · New England Journal of Medicine · 2010 · 1.7K citations · Full text

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Hagop M. Kantarjian, Andreas Hochhaus, Giuseppe Saglio et al. · The Lancet Oncology · 2011 · 511 citations

Chronic Phase, Hematological Malignancy, Nilotinib Versus Imatinib +10

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Richard A. Larson, Andreas Hochhaus, Timothy P. Hughes et al. · Leukemia · 2012 · 437 citations

Chronic Phase, Chromatin, Hematological Malignancy +8

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

Hagop M. Kantarjian, Francis J. Giles, Kapil N. Bhalla et al. · Blood · 2010 · 376 citations · Full text

Activation of the p38 Mitogen-activated Protein Kinase Pathway by Epstein-Barr Virus-encoded Latent Membrane Protein 1 Coregulates Interleukin-6 and Interleukin-8 Production

Aristides G. Eliopoulos, Neil J. Gallagher, Sarah M.S. Blake et al. · Journal of Biological Chemistry · 1999 · 347 citations · Full text